<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293562</url>
  </required_header>
  <id_info>
    <org_study_id>AAML1831</org_study_id>
    <secondary_id>NCI-2020-00546</secondary_id>
    <secondary_id>AAML1831</secondary_id>
    <secondary_id>AAML1831</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT04293562</nct_id>
  </id_info>
  <brief_title>A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations</brief_title>
  <official_title>A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or&#xD;
      gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3&#xD;
      mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab&#xD;
      ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up&#xD;
      of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone&#xD;
      marrow longer and could be less likely to cause heart problems than traditional anthracycline&#xD;
      drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an&#xD;
      abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that&#xD;
      carry instructions for development, functioning, growth and reproduction) inside each cell&#xD;
      that tell the cell what to do and when to grow and divide. FLT3 plays an important role in&#xD;
      the normal making of blood cells. This gene can have permanent changes that cause it to&#xD;
      function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function&#xD;
      of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to&#xD;
      compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people&#xD;
      with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or&#xD;
      bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or&#xD;
      other FLT3 mutations and 3) to study changes in heart function during and after treatment for&#xD;
      AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in&#xD;
      treating patients with acute myeloid leukemia compared to standard chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare event-free survival (EFS) in children with de novo acute myeloid leukemia (AML)&#xD;
      without FLT3 mutations who are randomly assigned to standard induction therapy on Arm A with&#xD;
      daunorubicin, cytarabine (DA) and gemtuzumab ozogamicin (GO) (DA-GO) versus Arm B with&#xD;
      liposome-encapsulated daunorubicin-cytarabine (CPX-351) and GO.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare overall survival (OS) and rates of end of Induction 1 (EOI1) minimal residual&#xD;
      disease (MRD) in children with de novo AML without FLT3 mutations who are randomly assigned&#xD;
      to standard induction therapy (Arm A) with DA-GO versus CPX-351 and GO (Arm B).&#xD;
&#xD;
      II. To estimate the EFS and rate of EOI1 MRD in FLT3 internal tandem duplication mutation&#xD;
      positive patients (FLT3/ITD+; as defined by allelic ratio &gt; 0.1) without favorable&#xD;
      cytomolecular characteristics (NPM1 and/or CEBPA) receiving gilteritinib fumarate&#xD;
      (gilteritinib) in combination with DA-GO (Arm AC).&#xD;
&#xD;
      III. To estimate the EFS and rate of EOI1 MRD in patients with non-ITD FLT3 activating&#xD;
      mutations who receive backbone therapy (DA-GO or CPX-351 and GO) with gilteritinib (Arms AD&#xD;
      and BD).&#xD;
&#xD;
      IV. To determine the feasibility of combining gilteritinib and DA-GO or CPX-351 and GO in&#xD;
      patients with FLT3/ITD mutations (Arm AC/Arm BC/Arm AD/Arm BD).&#xD;
&#xD;
      V. To compare EOI1 MRD and EFS in patients with FLT3/ITD AML+ (allelic ratio [AR] &gt; 0.1)&#xD;
      without favorable cytogenetic/molecular characteristics treated with DA-GO-gilteritinib&#xD;
      versus (vs) CPX-GO-gilteritinib (Arm AC vs Arm BC).&#xD;
&#xD;
      VI. To compare the incidence of significant left ventricular systolic dysfunction (LVSD) in&#xD;
      children with de novo AML without FLT3 mutations who are randomly assigned to standard&#xD;
      induction therapy (Arm A) with DA-GO versus CPX-351 and GO (Arm B).&#xD;
&#xD;
      VII. To compare the changes in echocardiography-derived measures of cardiac function,&#xD;
      including left ventricular ejection fraction (EF) and global longitudinal strain (GLS),&#xD;
      throughout AML therapy in patients with low and high risk AML without FLT3 mutations&#xD;
      receiving Arm A vs Arm B.&#xD;
&#xD;
      VIII. Determine if early changes in sensitive echocardiographic measures of cardiac function&#xD;
      (i.e., post-Induction 1 decline in GLS) and elevations in circulating cardiac biomarkers&#xD;
      (i.e., cardiac troponin T and N-terminal pro b-type natriuretic peptide) are associated with&#xD;
      subsequent declines in left ventricular ejection fraction in patients with non-FLT3 mutant&#xD;
      AML receiving therapy on Arms A or B.&#xD;
&#xD;
      IX. To compare longitudinal acute changes in neuropsychological functioning and&#xD;
      neurocognitive late effects between those with central nervous system (CNS) disease and those&#xD;
      without CNS disease and between those treated with hematopoietic stem cell transplant (HSCT)&#xD;
      and those treated with chemotherapy only for patients on Arms A and B.&#xD;
&#xD;
      X. To compare cardiotoxicity measures (EF, GLS, and cardiac biomarkers) in patients receiving&#xD;
      standard induction with dexrazoxane hydrochloride (dexrazoxane) vs. CPX-351 in the context of&#xD;
      gilteritinib therapy and explore whether the differential cardiotoxicity across arms varies&#xD;
      from that observed in non-FLT3 mutant AML without gilteritinib exposure.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the EFS and rate of EOI1 MRD in patients with high allelic ratio (HAR)&#xD;
      FLT3/ITD+ patients, as historically defined by an AR &gt; 0.4, receiving gilteritinib in&#xD;
      combination with DA-GO (Arm AC with AR &gt; 0.4).&#xD;
&#xD;
      II. To estimate the EFS and rate of EOI1 MRD in FLT3/ITD+ patients (as defined by allelic&#xD;
      ratio &gt; 0.1) with NPM1 and/or bZIP CEBPA mutations receiving gilteritinib in combination with&#xD;
      DA-GO (Arm AC).&#xD;
&#xD;
      III. Compare the changes in high sensitivity troponin and natriuretic peptide elevations&#xD;
      throughout AML therapy, as measured at the end of each chemotherapy course, in patients with&#xD;
      low and high risk AML without FLT3 mutations receiving Arm A vs Arm B.&#xD;
&#xD;
      IV. Quantify the association of host factors (age, sex, body mass index [BMI], race),&#xD;
      treatment exposures (cumulative anthracycline dose, anthracycline arm, hematopoietic stem&#xD;
      cell transplant vs. chemotherapy alone), early declines in GLS, and elevations in cardiac&#xD;
      biomarkers (cTnT and NT-proBNP) with subsequent LVSD.&#xD;
&#xD;
      V. Develop a multi-marker risk prediction model incorporating significant host factors,&#xD;
      treatment exposures, and echocardiographic predictors for the development of LVSD within 1&#xD;
      year of completing therapy.&#xD;
&#xD;
      VI. To describe the rates of CNS disease utilizing an updated strategy for diagnosing and&#xD;
      defining CNS disease in pediatric AML.&#xD;
&#xD;
      VII. To describe the rates of CNS relapse (both isolated CNS and combined bone marrow/CNS)&#xD;
      when utilizing this updated strategy as well as changing CNS prophylaxis and treatment to&#xD;
      include triple intrathecal chemotherapy.&#xD;
&#xD;
      VIII. To describe disease-free survival (DFS) and overall survival (OS) in high risk patients&#xD;
      based on multi-dimensional flow cytometry detection of measurable residual disease prior to&#xD;
      hematopoietic stem cell transplant (HSCT).&#xD;
&#xD;
      IX. To describe plasma metabolomics that may impact efficacy, toxicity, and/or&#xD;
      pharmacokinetics of allogeneic HSCT.&#xD;
&#xD;
      X. To estimate the prevalence of non-risk stratifying cytogenetic/molecular variants and&#xD;
      assess their impact on outcome in childhood AML.&#xD;
&#xD;
      OUTLINE: Patients are randomized to either Arm A or B and assigned to Arm C or D based on&#xD;
      FLT3 testing results.&#xD;
&#xD;
      TREATMENT FOR PATIENTS WITHOUT FLT3 MUTATIONS:&#xD;
&#xD;
      ARM A LOW RISK GROUP 1:&#xD;
&#xD;
      INDUCTION 1: Patients receive cytarabine intravenously (IV) over 1-30 minutes every 12 hours&#xD;
      (Q12H) on days 1-10, dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15 minutes&#xD;
      on days 1, 3, and 5, and gemtuzumab ozogamicin IV over 2 hours on day 6. Patients with CNS1&#xD;
      receive methotrexate intrathecally (IT), therapeutic hydrocortisone (hydrocortisone) IT, and&#xD;
      cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT once weekly (QW) starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the cerebral spinal fluid (CSF) is clear of blasts (CNS1&#xD;
      status). Patients with CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 1 for 6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive cytarabine IV over 1-30&#xD;
      minutes Q12H on days 1-8 and dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      INTENSIFICATION 2: Patients receive high-dose cytarabine IV over 3 hours Q12H on days 1, 2,&#xD;
      8, and 9. Patients also receive asparaginase Erwinia chrysanthemi intramuscularly (IM) or IV&#xD;
      over 1-2 hours and asparaginase IM or IV over 30 minutes on days 2 and 9.&#xD;
&#xD;
      ARM B LOW RISK GROUP 1:&#xD;
&#xD;
      INDUCTION 1: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab&#xD;
      ozogamicin IV over 2 hours on day 6. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive CPX-351 IV over 90&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      INTENSIFICATION 2: Patients receive high-dose cytarabine IV over 3 hours Q12H on days 1, 2,&#xD;
      8, and 9. Patients also receive asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9.&#xD;
&#xD;
      ARM A LOW RISK GROUP 2:&#xD;
&#xD;
      INDUCTION 1: Patients receive cytarabine IV over 1-30 minutes Q12H on days 1-10, dexrazoxane&#xD;
      IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and&#xD;
      gemtuzumab ozogamicin IV over 2 hours on day 6. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive cytarabine IV over 1-30&#xD;
      minutes Q12H on days 1-8 and dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      INTENSIFICATION 2: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H on days 1-4 and&#xD;
      dexrazoxane IV over 5-15 minutes and mitoxantrone hydrochloride (mitoxantrone) IV over 5-15&#xD;
      minutes on days 3-6.&#xD;
&#xD;
      INTENSIFICATION 3: Patients receive high-dose cytarabine IV over 3 hours Q12H on days 1, 2,&#xD;
      8, and 9. Patients also receive asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9.&#xD;
&#xD;
      ARM B LOW RISK GROUP 2:&#xD;
&#xD;
      INDUCTION 1: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab&#xD;
      ozogamicin IV over 2 hours on day 6. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive CPX-351 IV over 90&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      INTENSIFICATION 2: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H on days 1-4 and&#xD;
      dexrazoxane IV over 5-15 minutes and mitoxantrone hydrochloride (mitoxantrone) IV over 5-15&#xD;
      minutes on days 3-6.&#xD;
&#xD;
      INTENSIFICATION 3: Patients receive high-dose cytarabine IV over 3 hours Q12H on days 1, 2,&#xD;
      8, and 9. Patients also receive asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9.&#xD;
&#xD;
      ARM A HIGH RISK GROUP:&#xD;
&#xD;
      INDUCTION 1: Patients receive cytarabine IV over 1-30 minutes Q12H on days 1-10, dexrazoxane&#xD;
      IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and&#xD;
      gemtuzumab ozogamicin IV over 2 hours on day 6. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive cytarabine IV over 1-30&#xD;
      minutes Q12H on days 1-8 and dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      ARM B HIGH RISK GROUP:&#xD;
&#xD;
      INDUCTION 1: Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5, and gemtuzumab&#xD;
      ozogamicin IV over 2 hours on day 6. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2: Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW&#xD;
      starting on day 0 until CNS1 status is reached. Patients also receive CPX-351 IV over 90&#xD;
      minutes on days 1, 3, and 5.&#xD;
&#xD;
      INTENSIFICATION 1: Patients receive methotrexate IT, hydrocortisone IT, and cytarabine IT on&#xD;
      day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H and etoposide IV&#xD;
      over 90-120 minutes on days 1-5.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      TREATMENT FOR PATIENTS WITH FLT3/ITD MUTATIONS (ITD AR &gt; 0.1):&#xD;
&#xD;
      ARM AC LOW RISK GROUP 2:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive cytarabine IV over 1-30 minutes&#xD;
      Q12H on days 1-10, dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib orally&#xD;
      (PO) once daily (QD) on days 11-31. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive cytarabine IV over 1-30 minutes Q12H on days 1-8, dexrazoxane IV over 5-15 minutes&#xD;
      and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and gilteritinib PO QD on days&#xD;
      11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      INTENSIFICATION 2 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      on days 1-4, dexrazoxane IV over 5-15 minutes and mitoxantrone IV over 5-15 minutes on days&#xD;
      3-6, and gilteritinib PO QD on days 7-34.&#xD;
&#xD;
      INTENSIFICATION 3 (WITH GILTERITINIB): Patients receive high-dose cytarabine IV over 3 hours&#xD;
      Q12H on days 1, 2, 8, and 9, asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9, and gilteritinib PO QD on days 10-37.&#xD;
&#xD;
      POST-CHEMOTHERAPY GILTERITINIB MAINTENANCE: Patients receive gilteritinib PO QD or via&#xD;
      nasogastric (NG) or gastronomy (G) tube daily on days 1-365.&#xD;
&#xD;
      ARM BC LOW RISK GROUP 2:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive CPX-351 IV over 90 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib PO QD on&#xD;
      days 11-31. Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 8. Patients with CNS2, CNS3a, and CNS3b receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT QW starting on day 8 for 4-6 weeks (may continue into Induction 2) until&#xD;
      the CSF is clear of blasts (CNS1 status). Patients with CNS3c receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT QW starting on day 1 for 6 weeks (may continue into&#xD;
      Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and gilteritinib PO QD on days 11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      INTENSIFICATION 2 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      on days 1-4, dexrazoxane IV over 5-15 minutes and mitoxantrone IV over 5-15 minutes on days&#xD;
      3-6, and gilteritinib PO QD on days 7-34.&#xD;
&#xD;
      INTENSIFICATION 3 (WITH GILTERITINIB): Patients receive high-dose cytarabine IV over 3 hours&#xD;
      Q12H on days 1, 2, 8, and 9, asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9, and gilteritinib PO QD on days 10-37.&#xD;
&#xD;
      POST-CHEMOTHERAPY GILTERITINIB MAINTENANCE: Patients receive gilteritinib PO QD or via NG or&#xD;
      G tube daily on days 1-365.&#xD;
&#xD;
      ARM AC HIGH RISK GROUP:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive cytarabine IV over 1-30 minutes&#xD;
      Q12H on days 1-10, dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib orally&#xD;
      (PO) once daily (QD) on days 11-31. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive cytarabine IV over 1-30 minutes Q12H on days 1-8, dexrazoxane IV over 5-15 minutes&#xD;
      and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and gilteritinib PO QD on days&#xD;
      11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      POST-HSCT GILTERITINIB MAINTENANCE: Beginning 30-120 days after completion of HSCT, patients&#xD;
      receive gilteritinib PO QD or via NG or G tube daily on days 1-365.&#xD;
&#xD;
      ARM BC HIGH RISK GROUP:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive CPX-351 IV over 90 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib PO QD on&#xD;
      days 11-31. Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 8. Patients with CNS2, CNS3a, and CNS3b receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT QW starting on day 8 for 4-6 weeks (may continue into Induction 2) until&#xD;
      the CSF is clear of blasts (CNS1 status). Patients with CNS3c receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT QW starting on day 1 for 6 weeks (may continue into&#xD;
      Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and gilteritinib PO QD on days 11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      POST-HSCT GILTERITINIB MAINTENANCE: Beginning 30-120 days after completion of HSCT, patients&#xD;
      receive gilteritinib PO QD or via NG or G tube daily on days 1-365.&#xD;
&#xD;
      TREATMENT FOR NON-ITD FLT3 ACTIVATING MUTATIONS:&#xD;
&#xD;
      ARM AD LOW RISK GROUP 2:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive cytarabine IV over 1-30 minutes&#xD;
      Q12H on days 1-10, dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib orally&#xD;
      (PO) once daily (QD) on days 11-31. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive cytarabine IV over 1-30 minutes Q12H on days 1-8, dexrazoxane IV over 5-15 minutes&#xD;
      and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and gilteritinib PO QD on days&#xD;
      11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      INTENSIFICATION 2 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      on days 1-4, dexrazoxane IV over 5-15 minutes and mitoxantrone IV over 5-15 minutes on days&#xD;
      3-6, and gilteritinib PO QD on days 7-34.&#xD;
&#xD;
      INTENSIFICATION 3 (WITH GILTERITINIB): Patients receive high-dose cytarabine IV over 3 hours&#xD;
      Q12H on days 1, 2, 8, and 9, asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9, and gilteritinib PO QD on days 10-37.&#xD;
&#xD;
      POST-CHEMOTHERAPY GILTERITINIB MAINTENANCE: Patients receive gilteritinib PO QD or via NG or&#xD;
      G tube daily on days 1-365.&#xD;
&#xD;
      ARM BD LOW RISK GROUP 2:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive CPX-351 IV over 90 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib PO QD on&#xD;
      days 11-31. Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 8. Patients with CNS2, CNS3a, and CNS3b receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT QW starting on day 8 for 4-6 weeks (may continue into Induction 2) until&#xD;
      the CSF is clear of blasts (CNS1 status). Patients with CNS3c receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT QW starting on day 1 for 6 weeks (may continue into&#xD;
      Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and gilteritinib PO QD on days 11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      INTENSIFICATION 2 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      on days 1-4, dexrazoxane IV over 5-15 minutes and mitoxantrone IV over 5-15 minutes on days&#xD;
      3-6, and gilteritinib PO QD on days 7-34.&#xD;
&#xD;
      INTENSIFICATION 3 (WITH GILTERITINIB): Patients receive high-dose cytarabine IV over 3 hours&#xD;
      Q12H on days 1, 2, 8, and 9, asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9, and gilteritinib PO QD on days 10-37.&#xD;
&#xD;
      POST-CHEMOTHERAPY GILTERITINIB MAINTENANCE: Patients receive gilteritinib PO QD or via NG or&#xD;
      G tube daily on days 1-365.&#xD;
&#xD;
      ARM AD HIGH RISK GROUP:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive cytarabine IV over 1-30 minutes&#xD;
      Q12H on days 1-10, dexrazoxane IV over 5-15 minutes and daunorubicin IV over 1-15 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib orally&#xD;
      (PO) once daily (QD) on days 11-31. Patients with CNS1 receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT on day 8. Patients with CNS2, CNS3a, and CNS3b receive&#xD;
      methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 8 for 4-6 weeks (may&#xD;
      continue into Induction 2) until the CSF is clear of blasts (CNS1 status). Patients with&#xD;
      CNS3c receive methotrexate IT, hydrocortisone IT, and cytarabine IT QW starting on day 1 for&#xD;
      6 weeks (may continue into Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive cytarabine IV over 1-30 minutes Q12H on days 1-8, dexrazoxane IV over 5-15 minutes&#xD;
      and daunorubicin IV over 1-15 minutes on days 1, 3, and 5, and gilteritinib PO QD on days&#xD;
      11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      POST-HSCT GILTERITINIB MAINTENANCE: Beginning 30-120 days after completion of HSCT, patients&#xD;
      receive gilteritinib PO QD or via NG or G tube daily on days 1-365.&#xD;
&#xD;
      ARM BD HIGH RISK GROUP:&#xD;
&#xD;
      CONTINUED INDUCTION 1 (WITH GILTERITINIB): Patients receive CPX-351 IV over 90 minutes on&#xD;
      days 1, 3, and 5, gemtuzumab ozogamicin IV over 2 hours on day 6, and gilteritinib PO QD on&#xD;
      days 11-31. Patients with CNS1 receive methotrexate IT, hydrocortisone IT, and cytarabine IT&#xD;
      on day 8. Patients with CNS2, CNS3a, and CNS3b receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT QW starting on day 8 for 4-6 weeks (may continue into Induction 2) until&#xD;
      the CSF is clear of blasts (CNS1 status). Patients with CNS3c receive methotrexate IT,&#xD;
      hydrocortisone IT, and cytarabine IT QW starting on day 1 for 6 weeks (may continue into&#xD;
      Induction 2).&#xD;
&#xD;
      INDUCTION 2 (WITH GILTERITINIB): Patients with CNS1 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT on day 0. Patients with CNS2 receive methotrexate IT, hydrocortisone&#xD;
      IT, and cytarabine IT QW starting on day 0 until CNS1 status is reached. Patients also&#xD;
      receive CPX-351 IV over 90 minutes on days 1, 3, and 5 and gilteritinib PO QD on days 11-38.&#xD;
&#xD;
      INTENSIFICATION 1 (WITH GILTERITINIB): Patients receive methotrexate IT, hydrocortisone IT,&#xD;
      and cytarabine IT on day 0. Patients also receive high-dose cytarabine IV over 1-3 hours Q12H&#xD;
      and etoposide IV over 90-120 minutes on days 1-5, and gilteritinib PO QD on days 6-33.&#xD;
&#xD;
      HSCT: After completion of Intensification 1 and investigator assigned conditioning regimen,&#xD;
      patients undergo allogeneic HSCT.&#xD;
&#xD;
      POST-HSCT GILTERITINIB MAINTENANCE: Beginning 30-120 days after completion of HSCT, patients&#xD;
      receive gilteritinib PO QD or via NG or G tube daily on days 1-365.&#xD;
&#xD;
      NOTE: During Induction 2 or Intensification 2, patients in Arms A and B with left ventricular&#xD;
      systolic dysfunction receive a replacement course of high-dose cytarabine IV over 3 hours on&#xD;
      days 1, 2, 8, and 9, and asparaginase Erwinia chrysanthemi IM or IV over 1-2 hours and&#xD;
      asparaginase IM or IV over 30 minutes on days 2 and 9. Patients in Arms AC, BC, AD, and BD&#xD;
      receive treatment as in Arms A and B and also receive gilteritinib PO QD on days 10-37&#xD;
      (Induction 2) or days 10-37 (Intensification 2).&#xD;
&#xD;
      All treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      OPTIONAL NEUROCOGNITIVE STUDY:&#xD;
&#xD;
      Patients may complete the Cogstate assessment battery at the end of Induction 1, at the end&#xD;
      of therapy, and at 9 and 60 months post-enrollment.&#xD;
&#xD;
      After completion of study treatment, patients are followed up monthly for 6 months and then&#xD;
      every other month for 6 months (year 1), every 4 months during year 2, every 6 months during&#xD;
      year 3, then yearly for years 4-10. Patients who undergo HSCT are also followed up at 30,&#xD;
      100, and 180 days, 9 months, and 1 year post-HSCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients positive for minimal residual disease (MRD+)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The proportion of patients MRD+ at end of induction 1 (EOI1) will be estimated as the number of patients MRD+ divided by the number of patients with evaluable EOI1 MRD results along with a corresponding 95% confidence interval determined using a binomial exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who died during protocol therapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of patients who died during protocol therapy will be estimated along with the corresponding 95% confidence interval determined using a binomial exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence estimates will be used to determine the 3 year relapse rate defined as time from study entry to induction failure or relapse where deaths or secondary malignancies are competing events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality rate (TRM)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence estimates will be used to determine the 3 year TRM defined as time from study entry to death where induction failure, relapse or secondary malignancies are competing events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of patients experiencing at least one grade 3 or higher non-hematologic toxicity and infection while on protocol therapy will be estimated along with the corresponding 95% confidence interval determined using a binomial exact method. Toxicity will be assessed by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Course duration</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median and range of the length of course duration will be determined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median and range of the length of hospitalization time during protocol therapy will be determined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to count recovery</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cumulative incidence estimates that account for competing events will be used to estimate time to count recovery in days where deaths are competing events.</description>
  </other_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A Low Risk Group 1: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm AC High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm AC Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm AD High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm AD Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B Low Risk Group 1: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm BC High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm BC Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm BD High Risk Group: See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm BD Low Risk Group 2: See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic HSCT</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <other_name>Allogeneic</other_name>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>ASP-1</other_name>
    <other_name>Asparaginase II</other_name>
    <other_name>Asparaginase-E.Coli</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-Asnase</other_name>
    <other_name>L-ASP</other_name>
    <other_name>L-Asparaginase</other_name>
    <other_name>L-Asparagine Amidohydrolase</other_name>
    <other_name>Laspar</other_name>
    <other_name>Lcf-ASP</other_name>
    <other_name>Leucogen</other_name>
    <other_name>Leunase</other_name>
    <other_name>MK-965</other_name>
    <other_name>Paronal</other_name>
    <other_name>Re-82-TAD-15</other_name>
    <other_name>Serasa</other_name>
    <other_name>Spectrila</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase Erwinia chrysanthemi</intervention_name>
    <description>Given IM or IV</description>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Crisantaspase</other_name>
    <other_name>Crisantaspasum</other_name>
    <other_name>Erwinase</other_name>
    <other_name>Erwinaze</other_name>
    <other_name>L-asparginase (Erwinia )</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cogstate Assessment Battery</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Cardioxane</other_name>
    <other_name>Totect</other_name>
    <other_name>Zinecard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</other_name>
    <other_name>CDP-771</other_name>
    <other_name>CMA-676</other_name>
    <other_name>gemtuzumab</other_name>
    <other_name>hP67.6-Calicheamicin</other_name>
    <other_name>Mylotarg</other_name>
    <other_name>WAY-CMA-676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib Fumarate</intervention_name>
    <description>Given PO or via NG or G tube</description>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>ASP-2215 Hemifumarate</other_name>
    <other_name>ASP2215 Hemifumarate</other_name>
    <other_name>Gilteritinib Hemifumarate</other_name>
    <other_name>Xospata</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposome-encapsulated Daunorubicin-Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>CPX-351</other_name>
    <other_name>Cytarabine-Daunorubicin Liposome for Injection</other_name>
    <other_name>Daunorubicin and Cytarabine (Liposomal)</other_name>
    <other_name>Liposomal AraC-Daunorubicin CPX-351</other_name>
    <other_name>Liposomal Cytarabine-Daunorubicin</other_name>
    <other_name>Liposome-encapsulated Combination of Daunorubicin and Cytarabine</other_name>
    <other_name>Vyxeos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Dihydroxyanthracenedione Dihydrochloride</other_name>
    <other_name>Mitoxantrone Dihydrochloride</other_name>
    <other_name>Mitoxantroni Hydrochloridum</other_name>
    <other_name>Mitozantrone Hydrochloride</other_name>
    <other_name>Mitroxone</other_name>
    <other_name>Neotalem</other_name>
    <other_name>Novantrone</other_name>
    <other_name>Onkotrone</other_name>
    <other_name>Pralifan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Hydrocortisone</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Arm A High Risk Group</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm A Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AC High Risk Group</arm_group_label>
    <arm_group_label>Arm AC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm AD High Risk Group</arm_group_label>
    <arm_group_label>Arm AD Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm B High Risk Group</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 1</arm_group_label>
    <arm_group_label>Arm B Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BC High Risk Group</arm_group_label>
    <arm_group_label>Arm BC Low Risk Group 2</arm_group_label>
    <arm_group_label>Arm BD High Risk Group</arm_group_label>
    <arm_group_label>Arm BD Low Risk Group 2</arm_group_label>
    <other_name>Aeroseb-HC</other_name>
    <other_name>Barseb HC</other_name>
    <other_name>Barseb-HC</other_name>
    <other_name>Cetacort</other_name>
    <other_name>Cort-Dome</other_name>
    <other_name>Cortef</other_name>
    <other_name>Cortenema</other_name>
    <other_name>Cortifan</other_name>
    <other_name>Cortisol</other_name>
    <other_name>Cortispray</other_name>
    <other_name>Cortril</other_name>
    <other_name>Dermacort</other_name>
    <other_name>Domolene</other_name>
    <other_name>Eldecort</other_name>
    <other_name>Hautosone</other_name>
    <other_name>Heb-Cort</other_name>
    <other_name>Hydrocortisone</other_name>
    <other_name>Hydrocortone</other_name>
    <other_name>Hytone</other_name>
    <other_name>Komed-HC</other_name>
    <other_name>Nutracort</other_name>
    <other_name>Proctocort</other_name>
    <other_name>Rectoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must be enrolled on APEC14B1 and consented to Eligibility Screening (Part&#xD;
             A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens&#xD;
             must be done according to the Manual of Procedures). Risk stratification will not be&#xD;
             possible without the submission of viable samples. Given there are multiple required&#xD;
             samples, bone marrow acquisition techniques such as frequent repositioning or&#xD;
             performing bilateral bone marrow testing should be considered to avoid insufficient&#xD;
             material for required studies. Consider a repeat marrow prior to starting treatment if&#xD;
             there is insufficient diagnostic material for the required studies&#xD;
&#xD;
          -  Patients must be less than 22 years of age at the time of study enrollment&#xD;
&#xD;
          -  Patient must be newly diagnosed with de novo AML according to the 2016 World Health&#xD;
             Organization (WHO) classification with or without extramedullary disease&#xD;
&#xD;
               -  Patient must have 1 of the following:&#xD;
&#xD;
                    -  &gt;= 20% bone marrow blasts (obtained within 14 days prior to enrollment)&#xD;
&#xD;
                         -  In cases where extensive fibrosis may result in a dry tap, blast count&#xD;
                            can be obtained from touch imprints or estimated from an adequate bone&#xD;
                            marrow core biopsy&#xD;
&#xD;
                    -  &lt; 20% bone marrow blasts with one or more of the genetic abnormalities&#xD;
                       (sample obtained within 14 days prior to enrollment)&#xD;
&#xD;
                    -  A complete blood count (CBC) documenting the presence of at least 1,000/uL&#xD;
                       (i.e., a white blood cell [WBC] count &gt;= 10,000/uL with &gt;= 10% blasts or a&#xD;
                       WBC count of &gt;= 5,000/uL with &gt;= 20% blasts) circulating leukemic cells&#xD;
                       (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed&#xD;
                       within 7 days prior to enrollment)&#xD;
&#xD;
          -  ARM C: Patient must be &gt;= 2 years of age at the time of Late Callback&#xD;
&#xD;
          -  ARM C: Patient must have FLT3/ITD allelic ratio &gt; 0.1 as reported by Molecular&#xD;
             Oncology&#xD;
&#xD;
          -  ARM C: Patient does not have any congenital long QT syndrome or congenital heart block&#xD;
&#xD;
          -  ARM C: Females of reproductive potential must agree to use effective contraception&#xD;
             during treatment and for at least 6 months after the last dose of gilteritinib&#xD;
&#xD;
          -  ARM C: Lactating women must agree not to breastfeed during treatment with gilteritinib&#xD;
             and for 2 months after the last dose of gilteritinib&#xD;
&#xD;
          -  ARM C: Males of reproductive potential must agree to use effective contraception&#xD;
             during treatment and for at least 4 months after the last dose of gilteritinib&#xD;
&#xD;
          -  ARM D: Patient must be &gt;= 2 years of age at the time of Late Callback&#xD;
&#xD;
          -  ARM D: Patient must have one of the clinically relevant non-ITD FLT3 activating&#xD;
             mutations as reported by Foundation Medicine&#xD;
&#xD;
          -  ARM D: Females of reproductive potential must agree to use effective contraception&#xD;
             during treatment and for at least 6 months after the last dose of gilteritinib&#xD;
&#xD;
          -  ARM D: Lactating women must agree not to breastfeed during treatment with gilteritinib&#xD;
             and for 2 months after the last dose of gilteritinib&#xD;
&#xD;
          -  ARM D: Males of reproductive potential must agree to use effective contraception&#xD;
             during treatment and for at least 4 months after the last dose of gilteritinib&#xD;
&#xD;
          -  NEUROPSYCHOLOGICAL TESTING: Patient must be enrolled on Arm A or Arm B. Patients who&#xD;
             transfer to Arm C or Arm D are not eligible&#xD;
&#xD;
          -  NEUROPSYCHOLOGICAL TESTING: Patient must be 5 years or older at the time of enrollment&#xD;
&#xD;
          -  NEUROPSYCHOLOGICAL TESTING: English-, French- or Spanish-speaking&#xD;
&#xD;
          -  NEUROPSYCHOLOGICAL TESTING: No known history of neurodevelopmental disorder prior to&#xD;
             diagnosis of AML (e.g., Down syndrome, fragile X, William syndrome, mental&#xD;
             retardation)&#xD;
&#xD;
          -  NEUROPSYCHOLOGICAL TESTING: No significant visual or motor impairment that would&#xD;
             prevent computer use or recognition of visual test stimuli&#xD;
&#xD;
          -  All patients and/or their parents or legal guardians must sign a written informed&#xD;
             consent&#xD;
&#xD;
          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute&#xD;
             (NCI) requirements for human studies must be met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with myeloid neoplasms with germline predisposition are not eligible&#xD;
&#xD;
          -  Fanconi anemia&#xD;
&#xD;
          -  Shwachman Diamond syndrome&#xD;
&#xD;
          -  Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21&#xD;
&#xD;
          -  Any other known bone marrow failure syndrome&#xD;
&#xD;
          -  Any concurrent malignancy&#xD;
&#xD;
          -  Juvenile myelomonocytic leukemia (JMML)&#xD;
&#xD;
          -  Philadelphia chromosome positive AML&#xD;
&#xD;
          -  Mixed phenotype acute leukemia&#xD;
&#xD;
          -  Acute promyelocytic leukemia&#xD;
&#xD;
          -  Acute myeloid leukemia arising from myelodysplasia&#xD;
&#xD;
          -  Therapy-related myeloid neoplasms&#xD;
&#xD;
          -  Administration of prior anti-cancer therapy except as outlined below:&#xD;
&#xD;
               -  Hydroxyurea&#xD;
&#xD;
               -  All-trans retinoic acid (ATRA)&#xD;
&#xD;
               -  Corticosteroids (any route)&#xD;
&#xD;
               -  Intrathecal therapy given at diagnosis&#xD;
&#xD;
               -  In particular, strong inducers of CYP3A4 and/or P-glycoprotein (P-gp) should be&#xD;
                  avoided from the time of enrollment until it is determined whether the patient&#xD;
                  will receive gilteritinib. Patients receiving gilteritinib will be required to&#xD;
                  avoid strong CYP3A4 inducers and/or strong P-gp inducers for the duration of the&#xD;
                  study treatment&#xD;
&#xD;
          -  Female patients who are pregnant since fetal toxicities and teratogenic effects have&#xD;
             been noted for several of the study drugs. A pregnancy test is required for female&#xD;
             patients of childbearing potential&#xD;
&#xD;
          -  Lactating females who plan to breastfeed their infants&#xD;
&#xD;
          -  Sexually active patients of reproductive potential who have not agreed to use an&#xD;
             effective contraceptive method for the duration of their study participation&#xD;
&#xD;
          -  ARM D: Patients with congenital long QT syndrome or congenital heart block are not&#xD;
             eligible for this treatment arm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd M Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>205-638-9285</phone>
      <email>oncologyresearch@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew A. Kutny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USA Health Strada Patient Care Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-388-8721</phone>
    </contact>
    <investigator>
      <last_name>Hamayun Imran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Children's at Desert</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>480-412-3100</phone>
    </contact>
    <investigator>
      <last_name>Joseph C. Torkildson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>602-546-0920</phone>
    </contact>
    <investigator>
      <last_name>Jessica Boklan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>aselegue@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Holly E. Pariury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>501-364-7373</phone>
    </contact>
    <investigator>
      <last_name>David L. Becton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Downey Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Robert M. Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Shilpa A. Shahani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>909-558-4050</phone>
    </contact>
    <investigator>
      <last_name>Albert Kheradpour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>562-933-5600</phone>
    </contact>
    <investigator>
      <last_name>Jacqueline N. Casillas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>323-361-4110</phone>
    </contact>
    <investigator>
      <last_name>Leo Mascarenhas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>310-423-8965</phone>
    </contact>
    <investigator>
      <last_name>Fataneh (Fae) Majlessipour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>310-825-6708</phone>
    </contact>
    <investigator>
      <last_name>William A. May</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>510-428-3324</phone>
      <email>Carla.Golden@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Carla B. Golden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-642-4691</phone>
      <email>Kpoct@kp.org</email>
    </contact>
    <investigator>
      <last_name>Laura A. Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>714-509-8646</phone>
      <email>oncresearch@choc.org</email>
    </contact>
    <investigator>
      <last_name>Elyssa M. Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Marcio H. Malogolowkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>858-966-5934</phone>
    </contact>
    <investigator>
      <last_name>William D. Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Benjamin J. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>805-682-7300</phone>
    </contact>
    <investigator>
      <last_name>David J. Slomiany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>303-764-5056</phone>
      <email>josh.b.gordon@nsmtp.kp.org</email>
    </contact>
    <investigator>
      <last_name>Kelly W. Maloney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>303-839-6000</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>860-545-9981</phone>
    </contact>
    <investigator>
      <last_name>Michael S. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>203-785-5702</phone>
      <email>canceranswers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Farzana Pashankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>302-651-6884</phone>
      <email>dperry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>202-444-2223</phone>
    </contact>
    <investigator>
      <last_name>Nina S. Kadan-Lottick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>202-884-2549</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey S. Dome</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>954-355-5346</phone>
    </contact>
    <investigator>
      <last_name>Hector M. Rodriguez-Cortes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>239-343-5333</phone>
      <email>molly.arnstrom@leehealth.org</email>
    </contact>
    <investigator>
      <last_name>Emad K. Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>352-273-8010</phone>
      <email>cancer-center@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>William B. Slayton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>954-265-1847</phone>
      <email>OHR@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Iftikhar Hanif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>904-697-3529</phone>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palms West Radiation Therapy</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Melissa S. Singer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Julio C. Barredo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>407-303-2090</phone>
      <email>FH.Cancer.Research@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Fouad M. Hajjar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>407-650-7715</phone>
    </contact>
    <investigator>
      <last_name>Emi H. Caywood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>850-416-4611</phone>
      <email>eebrou@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Erlyn C. Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>727-767-4784</phone>
      <email>Ashley.Repp@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer L. Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>813-844-7829</phone>
      <email>syapchanyk@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Juan F. Rico</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>813-357-0849</phone>
      <email>jennifer.manns@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Don E. Eslin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>561-881-2815</phone>
    </contact>
    <investigator>
      <last_name>Narayana Gowda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>404-785-2025</phone>
      <email>Leann.Schilling@choa.org</email>
    </contact>
    <investigator>
      <last_name>Himalee S. Sabnis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>706-721-2388</phone>
      <email>ga_cares@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Colleen H. McDonough</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>912-350-7887</phone>
      <email>Lorraine.OHara@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Andrew L. Pendleton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>808-983-6090</phone>
    </contact>
    <investigator>
      <last_name>Wade T. Kyono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute - Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>208-381-2774</phone>
      <email>eslinget@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Eugenia Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>773-880-4562</phone>
    </contact>
    <investigator>
      <last_name>Jenna Rossoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>312-355-3046</phone>
    </contact>
    <investigator>
      <last_name>Mary L. Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Eugene Suh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>847-723-7570</phone>
    </contact>
    <investigator>
      <last_name>Rebecca E. McFall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Park Ridge</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca E. McFall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-226-4343</phone>
    </contact>
    <investigator>
      <last_name>Jaime M. Libes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-545-7929</phone>
    </contact>
    <investigator>
      <last_name>Gregory P. Brandt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-248-1199</phone>
    </contact>
    <investigator>
      <last_name>Sandeep Batra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>317-338-2194</phone>
      <email>research@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Bassem I. Razzouk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-241-8912</phone>
      <email>samantha.mallory@unitypoint.org</email>
    </contact>
    <investigator>
      <last_name>Samantha L. Mallory</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>David S. Dickens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>James T. Badgett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>502-629-5500</phone>
      <email>CancerResource@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Ashok B. Raj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CHResearch@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Lolie C. Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>504-703-8712</phone>
      <email>Gregory.Johnstone@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Craig Lotterman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-396-7581</phone>
      <email>sverwys@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Eric C. Larsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Teresa A. York</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>410-601-6120</phone>
      <email>pridgely@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Jason M. Fixler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>410-955-8804</phone>
      <email>jhcccro@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Alan D. Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>301-319-2100</phone>
    </contact>
    <investigator>
      <last_name>Rebecca O. Clark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>617-636-5535</phone>
    </contact>
    <investigator>
      <last_name>Jason Law</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Howard J. Weinstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>John T. Horan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>508-856-3216</phone>
      <email>cancer.research@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Stefanie R. Lowas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Laura Sedig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Saint John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Adonis N. Lorenzana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>517-975-9547</phone>
    </contact>
    <investigator>
      <last_name>Aghiad Chamdin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Children's Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>248-551-7695</phone>
    </contact>
    <investigator>
      <last_name>Laura K. Gowans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>612-813-5193</phone>
    </contact>
    <investigator>
      <last_name>Michael K. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>612-624-2620</phone>
    </contact>
    <investigator>
      <last_name>Peter M. Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Mira Kohorst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>601-815-6700</phone>
    </contact>
    <investigator>
      <last_name>Anderson (Andy) B. Collier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>816-302-6808</phone>
      <email>rryan@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Keith J. August</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-268-4000</phone>
    </contact>
    <investigator>
      <last_name>William S. Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>314-251-7066</phone>
    </contact>
    <investigator>
      <last_name>Robin D. Hanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-955-3949</phone>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>402-559-6941</phone>
      <email>unmcrsa@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minnie Abromowitch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Childhood Diseases/Cure 4 the Kids Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>702-384-0013</phone>
      <email>research@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>Alan K. Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>201-996-2879</phone>
    </contact>
    <investigator>
      <last_name>Jing Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>973-971-5900</phone>
    </contact>
    <investigator>
      <last_name>Kathryn L. Laurie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-745-8600</phone>
      <phone_ext>6163</phone_ext>
      <email>kcovert@saintpetersuh.com</email>
    </contact>
    <investigator>
      <last_name>Nibal A. Zaghloul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-8675</phone>
    </contact>
    <investigator>
      <last_name>Richard A. Drachtman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>973-926-7230</phone>
      <email>Christine.Kosmides@rwjbh.org</email>
    </contact>
    <investigator>
      <last_name>Teena Bhatla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>973-754-2207</phone>
      <email>HallL@sjhmc.org</email>
    </contact>
    <investigator>
      <last_name>Alissa Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>518-262-5513</phone>
    </contact>
    <investigator>
      <last_name>Lauren R. Weintraub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>718-379-6866</phone>
      <email>eskwak@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Gennarini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>718-765-2500</phone>
    </contact>
    <investigator>
      <last_name>Mahmut Y. Celiker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Clare J. Twist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CancerTrials@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Mark E. Weinblatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-824-7309</phone>
      <email>CCTO@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Gary D. Crouch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-305-6361</phone>
      <email>nr2616@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Justine M. Kahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-639-7592</phone>
    </contact>
    <investigator>
      <last_name>Neerav N. Shukla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-746-1848</phone>
    </contact>
    <investigator>
      <last_name>Jennifer M. Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>585-275-5830</phone>
    </contact>
    <investigator>
      <last_name>Angela R. Girvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-862-2215</phone>
    </contact>
    <investigator>
      <last_name>Laura E. Hogan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>315-464-5476</phone>
    </contact>
    <investigator>
      <last_name>Philip M. Monteleone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>914-594-3794</phone>
    </contact>
    <investigator>
      <last_name>Jessica C. Hochberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>828-213-7055</phone>
      <email>NCDV.ResearchRegulatory@HCAHealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Douglas J. Scothorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart H. Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-804-9376</phone>
    </contact>
    <investigator>
      <last_name>Joel A. Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>980-201-6360</phone>
      <email>kashah@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Jessica A. Bell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-275-3853</phone>
    </contact>
    <investigator>
      <last_name>Lars M. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>252-744-1015</phone>
      <email>eubankss@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea R. Whitfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>David E. Kram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Broadway Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>701-323-5760</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Samuel J. Milanovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>330-543-3193</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Kuerbitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>513-636-2799</phone>
      <email>cancer@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Lauren Pommert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>216-844-5437</phone>
    </contact>
    <investigator>
      <last_name>Duncan S. Stearns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Rabi Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>614-072-2657</phone>
      <email>amy.yekisa@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Mark A. Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-228-4055</phone>
    </contact>
    <investigator>
      <last_name>Mukund G. Dole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>419-824-1842</phone>
    </contact>
    <investigator>
      <last_name>Jamie L. Dargart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>405-271-8777</phone>
      <email>ou-clinical-trials@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>503-413-2560</phone>
    </contact>
    <investigator>
      <last_name>Janice F. Olson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Bill H. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital-Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>734-712-3671</phone>
      <email>stephanie.couch@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Jacob A. Troutman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>570-271-5251</phone>
      <email>HemonCCTrials@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Jagadeesh Ramdas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>717-531-6012</phone>
    </contact>
    <investigator>
      <last_name>Lisa M. McGregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>267-425-5544</phone>
      <email>CancerTrials@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Aplenc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>215-427-8991</phone>
    </contact>
    <investigator>
      <last_name>Gregory E. Halligan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-692-8570</phone>
      <email>jean.tersak@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jean M. Tersak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>401-444-1488</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>843-792-9321</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline M. Kraveka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Richland Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Stuart L. Cramer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-241-6251</phone>
    </contact>
    <investigator>
      <last_name>Aniket Saha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>605-312-3320</phone>
      <email>OncologyClinicalTrialsSF@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Kayelyn J. Wagner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T C Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>865-331-1812</phone>
    </contact>
    <investigator>
      <last_name>Meghann P. McManus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>865-541-8266</phone>
    </contact>
    <investigator>
      <last_name>Susan E. Spiller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at TriStar Centennial</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>615-342-1919</phone>
    </contact>
    <investigator>
      <last_name>Haydar A. Frangoul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Sara Zarnegar-Lumley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>512-628-1902</phone>
      <email>TXAUS-DL-SFCHemonc.research@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Shannon M. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>361-694-5311</phone>
      <email>Crystal.DeLosSantos@dchstx.org</email>
    </contact>
    <investigator>
      <last_name>Nkechi I. Mba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>972-566-5588</phone>
    </contact>
    <investigator>
      <last_name>Stanton C. Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>214-648-7097</phone>
      <email>canceranswerline@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Tamra L. Slone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Paso Children's Hospital</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>915-298-5444</phone>
      <email>ranjan.bista@ttuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjan Bista</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>682-885-2103</phone>
      <email>CookChildrensResearch@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth M. Heym</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Alexandra M. Stevens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-632-6789</phone>
      <email>askmdanderson@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Najat C. Daw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>210-575-6240</phone>
      <email>Vinod.GidvaniDiaz@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Vinod K. Gidvani-Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>210-450-3800</phone>
      <email>phoresearchoffice@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie R. Langevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>254-724-5407</phone>
    </contact>
    <investigator>
      <last_name>Nicholas W. McGregor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>801-585-5270</phone>
    </contact>
    <investigator>
      <last_name>Mallorie B. Heneghan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont and State Agricultural College</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>802-656-8990</phone>
      <email>rpo@uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica L. Heath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>703-208-6650</phone>
      <email>Stephanie.VanBebber@inova.org</email>
    </contact>
    <investigator>
      <last_name>Robin Y. Dulman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>757-668-7243</phone>
      <email>CCBDCresearch@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Eric J. Lowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CTOclinops@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Jordyn R. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Children's</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>540-266-6238</phone>
      <email>wpmccarty@carilionclinic.org</email>
    </contact>
    <investigator>
      <last_name>Erwood G. Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-987-2000</phone>
    </contact>
    <investigator>
      <last_name>Sarah E. Leary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-228-6618</phone>
      <email>HopeBeginsHere@providence.org</email>
    </contact>
    <investigator>
      <last_name>Judy L. Felgenhauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>253-403-1461</phone>
      <email>research@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Robert G. Irwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>253-968-0129</phone>
      <email>mamcdci@amedd.army.mil</email>
    </contact>
    <investigator>
      <last_name>Melissa A. Forouhar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>304-388-9944</phone>
    </contact>
    <investigator>
      <last_name>Mohamad H. Badawi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>920-433-8889</phone>
      <email>ewd_research_admin@hshs.org</email>
    </contact>
    <investigator>
      <last_name>Catherine A. Long</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <investigator>
      <last_name>Kenneth B. De Santes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Center-Marshfield</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-782-8581</phone>
      <email>oncology.clinical.trials@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Michelle A. Manalang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-955-4727</phone>
      <email>MACCCTO@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Michael J. Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>780-407-6615</phone>
      <email>val.taylor@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Sarah J. McKillop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>866-561-1026</phone>
      <email>ctu_web@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Ashley Chopek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>902-470-8037</phone>
      <email>Research@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Erker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>905-521-2100</phone>
    </contact>
    <investigator>
      <last_name>Uma H. Athale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>613-738-3931</phone>
    </contact>
    <investigator>
      <last_name>Donna L. Johnston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>416-813-7654</phone>
      <email>ask.CRS@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Johann Hitzler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Montreal Children's Hospital of the MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>514-412-4445</phone>
      <email>info@thechildren.com</email>
    </contact>
    <investigator>
      <last_name>Sharon B. Abish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>514-345-4931</phone>
      <email>yvan.samson@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Yvan Samson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>418-525-4444</phone>
    </contact>
    <investigator>
      <last_name>Bruno Michon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>787-474-0333</phone>
    </contact>
    <investigator>
      <last_name>Maria E. Echevarria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Calicheamicins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

